##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 5 Download : 2

##plugins.themes.academic_pro.article.main##

Abstract

This  work  examined  the  diagnostic  role  of  biomarkers -APRI, alpha-fetoprotein–AFP  and gammaglutamine transpeptidase–GGTP before and after antiviral therapy in patients with different degrees of liver fibrosis. At the same time, there was a decrease in these indicators after treatment, which indicates a reverse development of liver fibrosis after specific therapy.During therapy, a significant decrease in APRI from 0.67 to 0.33 (p<0.05), AFP from 4.82 to 1.77 (p<0.01) and GGTP from 42.4 to 26.8 was established (p<0.05).  Thus,  APRI,  AFP  and  GGTP  indicators  can  be  used  as  dynamic  markers  for  assessing  the antifibroticeffect of etiotropic therapy for hepatitis C

Keywords

hepatitis C virus fibrosis APRI

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Bayjanov A.K, Nasirova Х.P, Khikmatullaeva A.S, Abdukadirova M.A, Yarmukhamedova N.A, Raximova V.Sh, Brigida K.S., Ibadullaeva N.S, Mirrakhimova N.M, Каn N, & Matyakubova Feruza Egamovna. (2024). Study Of Indirect Fibromarkers inIdentifying theDegree ofLiver Fibrosis During Antiviral Therapy Of Patients With Hepatitis HCV Etiology. Texas Journal of Medical Science, 37, 7–12. https://doi.org/10.62480/tjms.2024.vol37.pp7-12
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Аfdhal N., Everson G.T., Calleja J.L.et al. Effect of viral suppression on hepatic venouspressure gradient in hepatitis C with cirrhosis and portal hypertension.J. Viral. Hepat,2017. -No 24(10). –С. 823-831.2.Antonini T. M., Coilly A., Rossignol E. et al. ANRS C023 CUPILT study group. Sofosbuvir-based regimens in HIV/HCV coinfected patients after liver transplantation: results from the ANRS CO23 CUPILT study. Transplantation, 2018. –N 102(1). -Р. 119-126. 3.Foster G. R., Pianko S., Brown A. et al. BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology, 2015. –N 149(6). –P. 1462-1470.4.Ganesan M. К. Matrix stiffness regulate apoptopiccell death in HIV-HCV co-infected hepatocytes: Importance for liver fibrosis progression. Biochem Biophys Res Commun, 2018. –N 500. –P. 717-722.5.Hеzode C. Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients with HCV Genotype 1 Infection and Cirrhosis / Gastroenterology, 2014. -V. 147. -No 1. -P. 132-142.6.Konerman M. A., Mehta S. H., Sutcliffe C. G. et al. Fibrosis progression in human immunodeficiency virus/hepatitis Сvirus coinfected adults: prospective analysis of liver biopsy pairs. Hepatology, 2014. -V.59. -N3. -P. 767-775. 7.Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/AIDS Rep., 2012. Jun. –N. 9 (2). –P. 121-131.8.Lo Re V., Kallan M. J., Tate J. P. et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study // Ann Intern Med., 2014. Mar 18. -Vol. 160 (6). -Р. 369-379. doi: 10.7326/M13-1829.9.Poordad F., Schiff E. R., Vierling J. M. еt al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology, 2016. –N 63(5). –P. 1493-1505.10.Roger Ch., Ngoc W. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. Ann Intern Med, 2013. -Vol. 158. –N 11. –P. 807-820.11.Sulkowski M. S. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients coinfected with HIV-1: a randomized trial. JAMA, 2015. -Vol. 313 (12). -Р223-1231.12.Terilli R. R., Cox A. L. Immunity and hepatitis C: a review. Curr. HIV/AIDS Rep., 2013. -Vol. 10. -N 1. –Р. 51-58.